Patient Perceptions and Quality of Life Associated With the Use of Olapatadine 0.2% for the Treatment of Allergic Conjunctivitis
Phase 4
Completed
- Conditions
- Allergic Conjunctivitis
- Interventions
- Registration Number
- NCT01159769
- Lead Sponsor
- Alcon Research
- Brief Summary
The purpose of this study is to evaluate patient perceptions of olopatadine 0.2% dosed once daily in patients previously treated with twice-daily, topical, ocular, anti-allergy medications.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 215
Inclusion Criteria
- 12 years of age or older.
- History (within the past 24 months) of allergic conjunctivitis.
- Active signs and symptoms of ocular allergies.
- Ocular health within normal limits, as determined by the investigator or subinvestigator.
- Willing to avoid contact lens wear each study visit immediately prior to study medication instillation and for 10 minutes after instillation of study drug.
- Other protocol-defined inclusion criteria may apply.
Read More
Exclusion Criteria
- Contraindications or hypersensitivity to study medication or its components.
- One sighted eye or not correctable to 0.6 logMAR or better in both eyes at the screening visit.
- Known history of recurrent corneal erosion syndrome.
- Ocular trauma or surgical intervention within 6 months prior to Visit 1.
- Participation in any other investigational study within 30 days before Visit 1.
- Pregnant or nursing.
- Other protocol-defined exclusion criteria may apply.
Read More
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Olopatadine 0.2% Olopatadine hydrochloride ophthalmic solution, 0.2% (Pataday®) 1 drop self-administered in each eye once daily in the morning for 7 days
- Primary Outcome Measures
Name Time Method Overall Patient Satisfaction Day 7 Overall satisfaction was assessed by the patient on a questionnaire. The patient was instructed to select a single response to the statement, "Overall, how satisfied were you with olopatadine 0.2%?" A 5-point scale was used: very satisfied, satisfied, undecided, dissatisfied, very dissatisfied. Results are reported as the percentage of patients who responded, "very satisfied" or "satisfied."
- Secondary Outcome Measures
Name Time Method